Dopamine Cell Transplantation for Parkinson's Disease: The Importance of Controlled Clinical Trials

Neurotherapeutics

Volumn 8, Issue 4, 2011, Pages 549-561

  Freed, Curt R ^a   Zhou, Wenbo ^a   Breeze, Robert E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Caudate nucleus; Double blind trial; Embryonic stem cells; Fetal dopamine neurons; Immunosuppression; Induced pluripotent stem cells; Putamen

Indexed keywords

LEVODOPA;

BASAL GANGLION; CELL SURVIVAL; CELL TRANSPLANTATION; DOPAMINERGIC NERVE CELL; DYSKINESIA; IMMUNOSUPPRESSIVE TREATMENT; NEUROPHYSIOLOGY; NEUROSURGERY; PARKINSON DISEASE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PUTAMEN; REVIEW; TREATMENT OUTCOME;

ANIMALS; CELL TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; DOPAMINERGIC NEURONS; EMBRYONIC STEM CELLS; HUMANS; PARKINSON DISEASE;

EID: 80955157912     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0082-9     Document Type: Review

References (72)

1. Bjorklund A, Steveni U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177: 555-560.
2. Perlow MJ, Freed WJ, Hoffer BJ, et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979; 204: 555-560.
3. Freed CR, Breeze RE, Rosenberg NL, et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Arch Neurol 1990; 47: 505-512.
4. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574-577.
5. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327: 1549-1555.
6. Björklund A, Dunnett S, Brundin P, et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003; 2: 437-445.
7. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
8. Cohen J, New fight over fetal tissue grafts. Science 1994; 263: 600-601.
9. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-414.
10. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson Disease. Ann Neurol 2006; S59: 459-466.
11. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164-1172.
12. Goetz CG, Stebbins GT 3rd, Klawans HL, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology 1991; 41: 1719-1722.
13. Schumacher JM, Ellias SA, Palmer EP, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000; 54: 1042-1050.
14. Deacon T, Schumacher J, Dinsmore J, et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 1997; 3: 350-353.
15. Stover NP, Bakay RA, Subramanian T, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 2005; 62: 1833-1837.
16. Ungerstedt U, Arbuthoott CW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-493.
17. Dunnett SB, Hernandez TO, Summerfield A, Jones GH, Arbuthnott G. Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues. Exp Brain Res 1988; 71: 411-424.
18. Hudson JL, Bickford P, Johansson M, Hoffer BJ, Stromberg I. Target and neurotransmitter specificity of fetal central nervous system transplants: importance for functional reinnervation. J Neurosci 1994; 14: 283-290.
19. Mahalik TJ, Finger TE, Stromberg I, et al. Substantia nigra transplants into denervated srriatum of the rat: ultrastructure of graft and host interconnections. J Comp Neurol 1985; 240: 60-70.
20. Schmidt RH, Ingvar M, Lindvall O, et al. Functional activity of substantia nigra grafts reinnervating the striatum: neurotransmitter metabolism and (14C)-2-deoxy-D-glucose autoradiography. J. Neurochem 1982; 38: 737-748.
21. Wuerthele SM, Freed WJ, Olson L, et al. Effect of dopamine agonists and antagonists on the electrical activity of substantia nigra neurons transplanted into the lateral ventricle of the rat. Exp Brain Res 1981; 44: 1-10.
22. Brundin P, Nilsson OG, Strecker RE, Lindvall O, Astedt B, Bjorklund A. Behavioral effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res 1986; 65: 235-240.
23. Stromberg I, Bygdeman M, Goldstein M, Seiger A, Olson L. Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: evidence for functional reinnervation. Neurosci Lett 1986; 71: 271-276.
24. Davis GC, Williams AC, Markey SP, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1: 249-254.
25. Langston JW, Ballard P, Tetrud JW, Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
26. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983; 80: 4546-4550.
27. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Life Sci 1986; 39: 7-16.
28. Bakay RAE, Fiandaca MS, Barrow DL, et al. Preliminary report of the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like symptoms in primates. Appl Neurophysiol 1985; 48: 358-361.
29. Freed CR, Richards JB, Sabol KE, Reite ML. Fetal substantia nigra transplants lead to dopamine cell replacement and behavioral improvement in Bonnet monkeys with MPTP induced Parkinsonism. In: Pharmacology and Functional Regulation of Dopaminergic Neurons. Beart PM, Woodruff G, Jackson DM, eds. Macmillan Press, 1988: 353-360.
30. Annett LE, Martel FL, Rogers DC, Ridley RM, Baker HF, Dunnett SB. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 1994; 125: 228-246.
31. Annett LE, Torres EM, Clarke DJ, et al. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. Cell Transplant 1997; 6: 557-569.
32. Redmond DE, Sladek JR Jr, Roth RH, et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1986; 8490: 1125-1127.
33. Alexander GE, DeLong MR. Microstimulation of the primate neostriatum. II. Somatotopic organization of striatal microexcitable zones and their relation to neuronal response properties. J Neurophysiol 1985; 53: 1417-1430.
34. Hikosaka O, Sakamoto M, Usui S. Functional properties of monkey caudate neurons. I. Activities related to saccadic eye movements. J Neurophysiol 1989; 61: 780-798.
35. Hikosaka O, Sakamoto M, Usui S. Functional properties of monkey caudate neurons. III. Activities related to expectation of target and reward. J Neurophysiol 1989; 61: 814-832.
36. Kori A, Miyashita N, Kato M, Hikosaka O, Usui S, Matsumura M. Eye movements in monkeys with local dopamine depletion in the caudate nucleus. II. Deficits in voluntary saccades. J Neurosci 1995; 15: 928-941.
37. Annett LE, Torres EM, Ridley RM, Baker HF, Dunnett SB. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions. Exp Brain Res 1995; 103: 355-371.
38. Lindvall O, Rehncrona S, Brundin P, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. Arch Neurol 1989; 46: 615-631.
39. Spencer DD, Robbins RJ, Naftojin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327: 1541-1548.
40. Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by I -methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). N Engl J Med 1992; 327: l556-1563.
41. Peschanski M, Defer C, N'Guyen JP, et al. Bilateral motor improvement and lateralization of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117: 487-499.
42. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332: 1118-1124.
43. Freeman TB, Olanow CW, Hauser BA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38: 379-388.
44. Freed CR, Breeze RE, Schneck SA, et al. Fetal neural transplantation for Parkinson's disease. In: Rich RR, ed. Clinical Immunology, Principles and Practice. St. Louis: Mosby-Year Book, 1995: 1677-1687.
45. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, Weerasinghe S, King D, Desrosiers J, Darvesh S, Acorn T, Robertson H. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg. 2000; 92(5): 863-9.
46. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
47. Freeman TB, Sanberg PR, Nauert CM, et al. The influence of donor age on the survival of solid and suspension inrraparenchymal human embryonic nigral cells. Cell Transplant 1995; 4; 141-154.
48. Clarkson ED, Zawada WM, Adams FS, et al. Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats. Brain Res 1998; 806: 60-68.
49. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001; 50: 181-187.
50. Ma Y, Tang C, Chaly T, et al. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med 2010; 51: 7-15.
51. Ma Y, Feigin A, Dhawan V, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002; 52: 628-634.
52. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002; 5: 627-628.
53. Bateup HS, Santini E, Shen W, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 2010; 107: 14845-14850.
54. Gordon PH, Yu Q, Qualls C, et al. Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch Neurol 2004; 61: 858-861.
55. Trott CT, Fahn S, Greene P, et al. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology 2003; 60: 1938-1943.
56. Pakkenberg B, Moller A, Cundersen HJ, et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with unbiased stereological method. J Neurol Neurosurg Psychiatry 1991; 54: 30-33.
57. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington's: clinical, morphological and neurochemical correlations. J Neurol Science 1973; 20: 415-455.
58. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-880.
59. Freed CR, Zawada M, DeMasters BK, et al. Human embryonic dopamine neurons transplanted into Parkinson patients survive and improve motor function for at least 10 years without immunosuppression. Program No. 329. 6. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2005.
60. Zawada WM, Zastrow DJ, Clarkson ED, et al. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res 1998; 786: 96-103.
61. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506.
62. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503.
63. Mendez I, Viñuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008; 14: 507-509.
64. Buytaert-Hoefen KA, Alvarez E, Freed CR, Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after co-culture with cellular substrates and exposure to GDNF. Stem Cells 2004; 22: 669-674.
65. Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci 2004; 101: 12543-12548.
66. Yan Y, Yang D, Zarnowska ED, et al. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 2005; 23: 781-790.
67. Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009; 27: 2667-2674.
68. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006; 12: 1259-1268.
69. Chiba S, Lee YM, Zhou W, Freed CR. Noggin enhances dopamine neuron production from human embryonic stem cells and improves behavioral outcome after transplantation into Parkinsonian rats. Stem Cells 2008; 26: 2810-2820.
70. Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A 2010; 107: 15921-15926.
71. Chung S, Moon JI, Leung A, et al. ES cell-derived renewable and functional midbrain dopaminergic progenitors. Proc Natl Acad Sci U S A 2011; 108: 9703-9708.
72. Greene PE, Fahn S, Eidelberg D, Bjugstad KB, Breeze RE, and Freed CR. Persistent dyskinesias as a complication of fetal tissue transplantation for the treatment of Parkinson's disease. Movement Disorders, 2011, in press.